Phase I Dose Escalation/Dose Expansion Trial of NBTXR3/SBRT in Combination with Nivolumab or Pembrolizumab for the Treatment of Anti-PD-1 Naïve or Resistant Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
C. Shen(University of North Carolina at Chapel Hill), A.J. Rosenberg(University of Chicago), Ammar Sukari(The Barbara Ann Karmanos Cancer Institute), William Stokes(Emory University), T. Hackman(University of North Carolina at Chapel Hill), Jessica M. Frakes(Moffitt Cancer Center), Omar I. Vivar(Nanobiotix (France)), Kedar Kirtane(Moffitt Cancer Center), Nabil F. Saba(Emory University), Po‐Cheng Chang(University of Chicago), Z. Gooi(University of Chicago), Matthias Löhr(Karolinska University Hospital), A. Juloori(University of Chicago), Jessica Weiss(University of Toronto), D Rolando(Nanobiotix (France)), G.Q. Yang(Moffitt Cancer Center), J.J. Caudell(Moffitt Cancer Center), Septimiu Murgu(University of Chicago), Joey Wing Yan Chan(Chinese University of Hong Kong)
International Journal of Radiation Oncology*Biology*Physics
September 1, 2025
Cited by 1
Related Papers
United European Gastroenterology evidence‐based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU)
|United European Gastroenterology Journal|2017|698
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
|Journal of Clinical Oncology|2017|652
A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis
|Nature Genetics|2006|250
Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck: ASCO Guideline
|Journal of Clinical Oncology|2020|221
Associations of timing of physical activity with all-cause and cause-specific mortality in a prospective cohort study
|Nature Communications|2023|158